Guillaume Bayer

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Jérôme Avouac, Élodie Drumez, É. Hachulla et al. · The Lancet Rheumatology · 2021 · 290 citations · Full text

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +9

Etiology and Outcomes of Thrombotic Microangiopathies

Guillaume Bayer, Florent Von Tokarski, Benjamin Thoreau et al. · Clinical Journal of the American Society of Nephrology · 2019 · 155 citations · Full text

Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study

Guillaume Bayer, Marie‐Sara Agier, Bertrand Lioger et al. · European Journal of Internal Medicine · 2019 · 47 citations · Full text

Rheumatology, Lymphoid Neoplasia, Rituximab-induced Serum Sickness +15

White blood count, D‐dimers, and ferritin levels as predictive factors of pulmonary embolism suspected upon admission in noncritically ill COVID‐19 patients: The French multicenter CLOTVID retrospective study

J. Galland, Benjamin Thoreau, Maxime Delrue et al. · European Journal Of Haematology · 2021 · 23 citations · Full text

D-Dimer Level and Neutrophils Count as Predictive and Prognostic Factors of Pulmonary Embolism in Severe Non-ICU COVID-19 Patients

Benjamin Thoreau, Joris Galland, Maxime Delrue et al. · Viruses · 2021 · 23 citations · Full text